《大行報告》高盛升名創優品(09896.HK)目標價至54元 續列確信買入名單
高盛發表研究報告指,名創優品(09896.HK)上季銷售額按年增40%,淨收入增153%。國內業務繼續保持穩健增長,在品牌升級帶動毛利率強勁擴張的基礎上,門店擴張、商品交易總額及門店復甦的推動下,銷售額增長38%。此外,集團的海外業務銷售額和利潤率超出預期,進一步證明公司具有強勁的增長趨勢。
管理層維持對今年全年開店目標,目標是將中國的門店數量增加至5,000間。管理層又預計,長遠知識產權(IP)產品將佔銷售組合的25%至30%。該行將集團2024至25財年的純利預測上調約10%,目標升至54元,續列入確信買入名單。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.